102 related articles for article (PubMed ID: 1411636)
1. Absolute bioavailability and pharmacokinetics of oral teniposide.
Splinter TA; Holthuis JJ; Kok TC; Post MH
Semin Oncol; 1992 Apr; 19(2 Suppl 6):28-34. PubMed ID: 1411636
[TBL] [Abstract][Full Text] [Related]
2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of oral teniposide (VM-26).
Smit EF; Ousterhuis BE; Berendsen HH; Sleijfer DT; Postmus PE
Semin Oncol; 1992 Apr; 19(2 Suppl 6):35-9. PubMed ID: 1329226
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of daily oral teniposide for 20 days.
Smit EF; Splinter TA; Kok TC
Semin Oncol; 1992 Apr; 19(2 Suppl 6):40-2. PubMed ID: 1411637
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
7. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
Clark PI
Semin Oncol; 1992 Apr; 19(2 Suppl 6):20-7. PubMed ID: 1411635
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of teniposide in patients with ovarian cancer.
D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
[TBL] [Abstract][Full Text] [Related]
12. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
Hughes AN; Rafi I; Griffin MJ; Calvert AH; Newell DR; Calvete JA; Johnston A; Clendeninn N; Boddy AV
Clin Cancer Res; 1999 Jan; 5(1):111-8. PubMed ID: 9918208
[TBL] [Abstract][Full Text] [Related]
13. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
[TBL] [Abstract][Full Text] [Related]
15. Variability in the oral bioavailability of all-trans-retinoic acid.
Adamson PC; Pitot HC; Balis FM; Rubin J; Murphy RF; Poplack DG
J Natl Cancer Inst; 1993 Jun; 85(12):993-6. PubMed ID: 8388479
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
Figoli F; Zanette ML; Tirelli U; Sorio R; Lestuzzi C; Urso R; Monfardini S; D'Incalci M
Cancer Chemother Pharmacol; 1987; 20(3):239-42. PubMed ID: 2824081
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients.
Fujiwara Y; Ohune T; Okusaki K; Niitani K; Sumiyoshi H; Takemoto Y; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1996; 37(4):327-31. PubMed ID: 8548877
[TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacology of etoposide and teniposide.
Clark PI; Slevin ML
Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
20. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
